Biopharmaceutical company Appili Therapeutics Inc. announced that it will receive a $3 million grant from the U.S. Department of Defense to fund its AT1-1503 antibiotic program, which targets gram-negative ESKAPE pathogens.

ESKAPE pathogens — Enterococcus faeciumStaphylococcus aureusKlebsiella pneumoniaeAcinetobacter baumanniiPseudomonas aeruginosa, and Enterobacter species — have become increasingly problematic in recent years because of the overuse of antibiotics in agriculture and clinical practices.

Image by David Mark from Pixabay

Read more at Healio…